“Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s662. Accessed April 29, 2026. https://skin.dermsquared.com/skin/article/view/3848.